Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 9, 2009, Pages 3381-3386

  Vannucchi, G ^a   Campi, I ^a   Covelli, D ^a   Dazzi, D ^b   Curro N ^a   Simonetta, S ^a   Ratiglia, R ^a   Beck Peccoz, P ^a   Salvi, M ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale di Fidenza   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; IODINE 131; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; FEMALE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 69949106283     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0506     Document Type: Article

References (25)

1. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Mazzi B, Rocchi R, Barbesino G, Pinchera A 1999 Graves' ophthalmopathy and 131I therapy. Q J Nucl Med 43:307-312
2. Rasmussen AK, Nygaard B, Feldt-Rasmussen U 2000 (131)I and thyroid-associated ophthalmopathy. Eur J Endocrinol 143:155-160
3. Bonnema SJ, Bartalena L, Toft AD, Hegedüs L 2002 Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 147:1-11 (Pubitemid 34814734)
4. Gorman CA 1995 Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 80:340-342
5. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150:1098-1101 (Pubitemid 20155338)
6. Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR 2008 Radioiodine therapy and Graves' ophthalmopathy. J Nucl Med 49:923-930
7. Tallstedt L, Lundell G, Tørring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738
8. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78 (Pubitemid 28042269)
9. Kung AW, Yau CC, Cheng A 1994 The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 79:542-546 (Pubitemid 24256550)
10. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P 2008 Radioiodine therapy for Graves' disease and the effect on ophthalmopathy - a systematic review. Clin Endocrinol (Oxf) 69:943-950
11. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A 1998 Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632-635 (Pubitemid 28480819)
12. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464-3470 (Pubitemid 44402120)
13. Tallstedt L, Lundell G, Blomgren H, Bring J 1994 Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494-497
14. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J 2005 A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321-5323 (Pubitemid 41262294)
15. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273-285
16. Tanda ML, Lai A, Bartalena L 2008 Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions. Clin Endocrinol (Oxf) 69:845-847
17. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L 1997 Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47:9-14 (Pubitemid 27313981)
18. Werner SC 1977 Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 83:725-727 (Pubitemid 8136099)
19. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O 2008 TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69-75 (Pubitemid 351211042)
20. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A 1989 Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321:1349-1352 (Pubitemid 19284190)
21. Armengol MP, Juan M, Lucas-Martín A, Fernández-Figueras MT, Jaraquemada D, Gallart T, Pujol-Borrell R 2001 Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 159:861-873 (Pubitemid 32847177)
22. Aust G, Sittig D, Becherer L, Anderegg U, Schütz A, Lamesch P, Schmücking E 2004 The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur J Endocrinol 150:225-234 (Pubitemid 38312815)
23. Ho VH, Chevez-Barrios P, Jorgensen JL, Silkiss RZ, Silkis RZ, Esmaeli B 2007 Receptor expression in orbital inflammatory syndromes and implications for targeted therapy. Tissue Antigens 70:105-109 (Pubitemid 47024830)
24. Weetman AP, Cohen S, Gatter KC, Fells P, Shine B 1989 Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 75:222-227 (Pubitemid 19074250)
25. Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P 2009 Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 131:360-365